When the Target Is SSRIs, the Risk Is the Six Protected Classes

On May 4, 2026, Health Secretary Robert F. Kennedy Jr. closed a daylong Make America Healthy Again (MAHA) Institute summit on mental health and overmedicalization by announcing a federal initiative to reduce the use of selective serotonin reuptake inhibitors (SSRIs). The package includes new Centers for Medicare & Medicaid Services (CMS) reimbursement codes for clinicians who help patients taper off antidepressants, forthcoming Substance Abuse and Mental Health Services Administration (SAMHSA) training modules, a technical expert panel to develop deprescribing clinical guidelines, and a "Dear Colleague" letter to providers urging non-pharmacologic alternatives. No major medical organizations participated in the summit. Kennedy described the goal as ending "unnecessary dependence on medication" and returning control to patients. For readers familiar with how Medicare Part D's six protected classes (6PC) have been contested over the past two decades, the announcement reads less as a discrete clinical reform than as a foothold.

What Was Announced, and What the Evidence Says

The administration's framing rests on contested and, in some cases, fabricated premises. Kennedy has claimed, without evidence, that SSRIs are partly responsible for school shootings, a claim he first advanced during his confirmation hearings and repeated at the May 4 summit. He has also stated that SSRIs are harder to quit than heroin. The withdrawal evidence is more measured: a 2019 British study reported 56% of patients experienced withdrawal symptoms, while a 2024 placebo-controlled German analysis found roughly one in six experienced withdrawal effects and about 3% described them as severe. Roughly 16.6% of U.S. adults currently take an SSRI, and the American Psychiatric Association (APA) considers SSRIs a first-line, evidence-based treatment for depression.

The APA called the administration's framing an "oversimplification" that "ignores the larger reality" of access barriers to mental health care. Dr. J. John Mann of the New York State Psychiatric Institute was more direct, telling Reuters that "restricting use of these medications is not justifiable medically". The American Foundation for Suicide Prevention emphasized that decades of clinical, population-level, and health-system data show judicious antidepressant use reduces suicide risk overall.

Some elements of the initiative are defensible. Better tapering support, stronger informed consent, and broader access to talk therapy reflect long-standing clinical recommendations. The concern lies in what surrounds those elements.

A Reported Exploration of a Ban

Four days after the summit, Reuters reported that two sources familiar with internal discussions said HHS officials had explored whether the agency could ban specific drugs within the SSRI class in the week before Kennedy's announcement. HHS spokesman Andrew Nixon denied the discussions had occurred. The Food and Drug Administration (FDA) does not have authority to unilaterally ban approved medications absent new safety evidence, and manufacturers can refuse withdrawal requests, as Amgen did with Tavneos in April 2026. The reporting does not establish that a ban is imminent. It does establish that the agency's internal direction outpaces its public posture.

What the 2004 Black Box Warning Should Teach Us

Federal messaging about antidepressant risk has a documented track record of producing harm. The FDA's 2003 and 2004 advisories, followed by the October 2004 boxed warning on pediatric antidepressants and its 2007 extension to young adults, were based on a meta-analysis never designed to measure suicidality and that recorded no completed suicides. Subsequent research by Stephen Soumerai and Christine Lu found that rates of depression diagnosis, clinical visits, and antidepressant prescribing dropped by roughly one-third, while youth suicide attempts and deaths rose. No study has demonstrated that the warnings improved mental health outcomes. The lesson: federal rhetoric that vilifies a class of medications drives patients away from care, and the patients who disengage are often those at highest risk.

Why This Reaches the Six Protected Classes

Antidepressants are one of six therapeutic classes that Part D plans must cover "all or substantially all" drugs within. The other five are anticonvulsants, antineoplastics, antipsychotics, antiretrovirals, and immunosuppressants. The policy was established through CMS guidance in 2005, codified by the Medicare Improvements for Patients and Providers Act in 2008, and reinforced by the Affordable Care Act in 2010. It exists because Congress recognized that insurers, left to their own design, would engage in adverse selection against the sickest enrollees.

The 6PC have been targeted before. In January 2014, CMS proposed removing protected status from antidepressants, antipsychotics, and immunosuppressants. The proposal was rescinded within two months after opposition from patient groups, providers, manufacturers, and lawmakers. In May 2018, the first Trump administration's "American Patients First" Blueprint signaled renewed interest in weakening 6PC protections. In January 2021, the CMS Innovation Center released a Part D Payment Modernization Model Request for Applications that would have allowed participating plans to bypass the 6PC requirement for five classes starting in 2022, and for antiretrovirals starting in 2023. The HIV Health Care Access Working Group, of which CANN is a member, warned that restricting antiretrovirals would produce disruptions to care, decreased rates of viral suppression, increased rates of new infections, and more drug resistant strains of HIV. The Biden administration rescinded those changes.

People living with HIV (PLWH) have an immediate stake in this fight. Co-occurring serious mental illness and substance use disorders are common among PLWH, and the same statutory architecture that guarantees access to antiretrovirals also guarantees access to antidepressants and antipsychotics. Erosion of that architecture for one class establishes precedent for the others. A 2024 Health Affairs analysis from Weill Cornell Medicine estimated that removing protected class regulation could have reduced prescription drug spending by approximately $47 billion between 2011 and 2019, a figure that will be cited by anyone seeking to revisit the policy. The savings argument is not hypothetical, and it is not new. What they fail to factor into the equation (or willfully ignore), is that those saved dollars equal lost treatment access for real patients. There is always a cost, this one would be human.

The Pattern Around the Initiative

The SSRI initiative is not arriving into a stable regulatory environment. Since January 2025, HHS has eliminated the Administration for Community Living, the only federal agency dedicated to community living and civil rights for disabled and older Americans. HHS Office for Civil Rights staffing was cut and half of its regional offices closed. On May 12, 2025, the administration paused 2024 final rules requiring insurers to disclose how they restrict mental health claims under the Mental Health Parity and Addiction Equity Act. H.R. 1, signed July 4, 2025, imposed Medicaid work requirements and reduced Medicaid funding by more than $1 trillion over a decade. The Leadership Conference Health Care Task Force described the cumulative effect as a "wholesale assault on public health."

A campaign to reduce SSRI use, taken on its own, would warrant clinical debate. Layered onto this regulatory environment, it warrants vigilance.

What Advocates Should Watch and Do

Several specific actions matter now. First, monitor SAMHSA's forthcoming prescribing trend data and the deprescribing clinical guidelines expected this summer. The language used to justify reduced antidepressant utilization can be repurposed against other protected classes, particularly antipsychotics, which share co-prescribing patterns with antiretrovirals among PLWH with serious mental illness. Second, watch CMS for any Part D rulemaking or demonstration authority that quietly modifies formulary requirements. The 2021 Payment Modernization Model was rescinded because a broad coalition of cancer, HIV, mental health, and disability advocates spoke with one voice; that coalition infrastructure should be reactivated and ready. Third, engage in any HHS comment period touching deprescribing guidance, formulary design, or utilization management. Fourth, document and report plan-level changes affecting antidepressant or antiretroviral access, including new prior authorization requirements or step therapy protocols. Fifth, communicate clearly with patients that current treatments remain covered and that medical decisions belong with them and their clinicians. The chilling effect documented after the 2004 black box warning was driven by media coverage, not by any actual loss of access. We can blunt that effect by keeping accurate information in front of the communities we serve.

For PLWH and the organizations that support them, the connection to Ending the HIV Epidemic is direct. Viral suppression depends on uninterrupted access to the right antiretroviral regimen for each patient, and that access depends on the statutory protections that the 6PC framework provides.

What Comes Next

The SSRI initiative may proceed entirely within the bounds of clinical policy. The deprescribing codes may improve care. The training modules may help clinicians who have long lacked tapering expertise. The protected classes may remain untouched. None of that is guaranteed, and the past eighteen months of HHS reorganization give us no reason to assume the most benign interpretation. What we can do is read the policy direction accurately, engage the regulatory process the way our coalitions have engaged it before, and keep the communities we serve informed. The six protected classes have survived three administrations' attempts to weaken them. Keeping them protected is ongoing work.

ADAPs Work. Federal Policy Is Defunding Them on Accident.

NASTAD released its 2026 National Ryan White HIV/AIDS Program (RWHAP) Part B AIDS Drug Assistance Program (ADAP) Monitoring Project Annual Report this month, and the numbers tell two stories at once. In 2024, state and territorial ADAPs served 257,644 people living with HIV across 49 reporting jurisdictions, achieving an 87% viral suppression rate among clients served. That figure significantly outpaces the estimated 67% suppression rate among all people living with diagnosed HIV in the United States, and it was achieved within a population where 65% of clients live at or below 200% of the Federal Poverty Level (FPL). By any clinical measure, ADAPs are delivering.

The second story is fiscal. Drug rebates generated through the 340B Drug Pricing Program now constitute 52% of total ADAP budgets, dwarfing the federal ADAP earmark at just 29%. A $2.7 billion safety net serving nearly one-quarter of all people living with diagnosed HIV in the country is now majority-funded by a revenue source that multiple federal policy changes are actively eroding. And demand is about to surge.

The Unwinding as Stress Test

The post-COVID Medicaid unwinding that began in April 2023 showed us what happens when coverage shifts push low-income people living with HIV off their insurance. ADAPs absorbed a 30% increase in new client enrollments and an 11% increase in total enrollment compared to 2022. Across 40 jurisdictions with comparable data, prescription drug spending grew 17% in two years, from $1.31 billion to $1.54 billion. Some states faced localized shocks: Pennsylvania's drug costs rose 82%, Arizona's nearly tripled. A JAMA Health Forum study confirmed that more than 25 million people nationally had Medicaid terminated during unwinding, with coverage losses concentrated among younger, healthier adults most likely to fall out of care when coverage disappears.

The system held. But the unwinding was a stress test, not the main event.

The Rebate Dependency Trap

Congressional appropriations for RWHAP Part B totaled $1.41 billion in FY2024, with ADAP-specific funding essentially flat. States have bridged the gap through 340B rebate revenue. In FY2019, 73% of rebates were applied to ADAP budgets; by FY2024, that figure reached 86%. Programs are retaining nearly every rebate dollar generated, and it still barely meets demand.

The Inflation Reduction Act (IRA) creates an unintended problem here. Its Medicare Part D reforms cap annual out-of-pocket drug costs at $2,000 in 2025 and $2,100 in 2026, which genuinely benefits Medicare beneficiaries. But ADAPs generate "partial-pay rebates" on cost-sharing payments made on behalf of clients enrolled in Medicare Part D. Lower cost-sharing means lower rebate revenue. The IRA's Medicare Drug Price Negotiation Program is likely to further compress the pricing benchmarks driving rebate calculations. The third negotiation round, announced in January 2026, selected Biktarvy for negotiated pricing effective in 2028. Biktarvy is the most widely prescribed single-tablet HIV regimen in the country and cost Medicare approximately $3.9 billion for 101,000 beneficiaries in the most recent measurement period. A negotiated reduction in Biktarvy's Medicare price could directly lower the "best price" benchmark that determines ADAP rebate revenue on the very drug that anchors most clients' treatment.

Layer on the PBM reform provisions signed into law in February 2026 requiring 100% rebate pass-through in Medicare Part D starting in 2028, plus manufacturer restrictions on 340B contract pharmacies that 54% of ADAPs report are creating payment challenges, and the picture is clear: the revenue stream funding more than half the HIV safety net is being squeezed from multiple directions, all at once, and the pressure is increasing.

Each of these policies may have merit on its own terms. But none were designed with a safety net impact assessment in mind, and the cumulative downstream effect on ADAP financing is significant and remains unaddressed.

The Demand Surge

While revenue contracts, demand is set to spike. H.R. 1, signed July 4, 2025, enacts the largest Medicaid cuts in the program's history. The Congressional Budget Office (CBO) estimates $911 billion in federal Medicaid spending reductions over a decade. KFF notes that more than 10.3 million people are likely to lose Medicaid. A Center for American Progress analysis found the bill's approximately $1 trillion in Medicaid cuts is roughly matched by approximately $1 trillion in tax reductions directed to the top 1% of earners. The priorities embedded in that budget math deserve scrutiny, to put it mildly.

And then the enhanced ACA premium tax credits expired at the end of 2025 without extension. Approximately 22 million people received those credits last year, and the average recipient has seen premiums more than double. The Urban Institute estimates roughly 5 million people may drop coverage and go uninsured, with the impact falling disproportionately on Black and low-income communities in metro areas like Houston and Atlanta, per the Economic Policy Institute. When the CBPP tallies all coverage losses, the total reaches roughly 15 million people newly uninsured by 2034.

For people living with HIV, these numbers carry specific weight. Medicaid is the single largest source of coverage for adults living with HIV at an estimated 40%, with 42% of those enrollees qualifying through the ACA expansion pathway H.R. 1's work requirements directly target. People living with HIV also rely on ACA Marketplace plans at higher rates than the general population; at least 40,000 ADAP clients were enrolled in Marketplace plans as of 2023. KFF estimates the premium tax credit expiration alone will cost state ADAPs an estimated $83.7 million in additional premium costs, with ADAPs in non-expansion states facing the steepest increases. If ADAPs cannot absorb those costs, KFF outlines the consequences: reduced income eligibility, restricted formularies, increased utilization management, and the possible return of waiting lists for the first time since 2012.

We don't have to speculate about what this looks like. On January 8, 2026, the Florida Department of Health announced sweeping changes to its ADAP, effective March 1: slashing income eligibility from 400% FPL to 130% FPL, eliminating insurance premium assistance, and removing Biktarvy from the formulary. NASTAD estimates more than 16,000 people will lose ADAP coverage. Florida cited rising premiums and the premium tax credit expiration, yet has not released an ADAP budget in over a year and bypassed the stakeholder engagement required under federal Ryan White guidelines. Every structural vulnerability the NASTAD report identifies played out in a single state in a matter of weeks.

What We Should Be Doing

The NASTAD report warns that H.R. 1 and the premium tax credit expiration threaten to "unravel the coverage gains" it documents. ADAPs serve 23% of all people living with diagnosed HIV. The Ending the HIV Epidemic (EHE) initiative depends on sustained viral suppression, which depends on treatment access, which depends on these programs remaining solvent. The data demands specific action. Short of reversing the policies of H.R. 1 and actually insuring poor people as a just and moral society might choose to do, several targeted measures could prevent the worst outcomes.

Congress should increase the federal ADAP earmark to reflect documented enrollment growth and the surge H.R. 1 will drive, and pursue RWHAP reauthorization to replace the year-to-year appropriations the program has relied on since its authorization lapsed in 2013. Flat funding in the face of 30% enrollment growth is a policy choice with consequences measured in lives.

Congress should reinstate and make permanent the enhanced ACA premium tax credits. For people already navigating the social determinants of health that create barriers to care, losing insurance coverage removes one of the few reliable pathways to sustained treatment access and viral suppression. Future drug pricing legislation should include safety net impact assessments to identify and offset downstream revenue effects on programs like ADAPs before those effects become crises.

States need targeted investment in ADAP administrative infrastructure to manage the coming enrollment wave. 60% of ADAPs already report maintaining client eligibility as challenging and 38% report difficulties implementing long-acting injectables and provider-administered drugs. The 30% enrollment surge during unwinding stretched existing capacity. What H.R. 1 delivers will be larger and longer-lasting.

The 2026 NASTAD report documents a system that works. An 87% viral suppression rate among a low-income population, achieved through sophisticated fiscal management and a decades-long commitment to keeping people in care, is a public health accomplishment we should be protecting. The question is whether we will defend the infrastructure that makes it possible, or let it collapse under the weight of policy decisions that were never designed to account for it.